Scientific research on gene and cellular therapies increased substantially over the last years. With Real World Data becoming increasingly available, many scientific questions, from different perspectives, can be explored. Only by working together can we leverage enough data to conduct meaningful research. GoCART wants to maximise the use of data collected in the central EBMT registry as well as data available to other stakeholders, and to facilitate further collaboration between stakeholders. While strongly protecting confidentiality, the guiding principle should be ‘collect once, use often’ to advance our knowledge in the field of gene and cellular therapies, support better decision making and drive efficiencies for all stakeholders.



Stimulate scientific discussion across stakeholders, facilitate the set-up of joint research projects and avoid duplication of scientific efforts.


Yearly calls for research proposals to promote the conduct of collaborative studies.



GoCART has released three calls for proposals, one in each of 2021, 2022 and 2023.

GoCART is supporting the following winning proposals from the calls in 2021 and 2022:
1. Impact of preceding therapy on the efficacy, safety and feasibility of anti-CD19 CAR T-cells in acute lymphoblastic leukaemia
2. Patterns of relapse after commercial use of anti-CD19 CART in patients with relapsed/refractory diffuse large B cell lymphoma
3. Autoimmune and auto inflammatory complications after CAR-T cell therapy
4. Infections following CAR-T therapy
5. Efficacy of CAR T-cell therapy in patients with primary and secondary central nervous system lymphoma

The studies are conducted by a dedicated GoCART Study Team based at EBMT consisting of a study coordinator, data manager and statisticians.

The third call for proposals has now closed – the winners will be announced in December 2023!

From 2024 we plan to have two calls for proposals per year.